Mann spent $1 billion of his own money to bring Afrezza to market. The Los Angeles Times reported he died in Las Vegas.
Just a week after leaving the board of a company he founded, MannKind founder Alfred E. Mann has died at age 90.
Mann, who died Thursday, was remembered as a philanthropist and entrepreneur who founded 17 companies, 3 of which became public. Ten were acquired at a value of more than $10 billion, according to GEN Highlights.
Almost half the total that total came from Medtronic’s acquisition of MiniMed, which developed insulin pumps for persons with diabetes.
A later diabetes venture to deliver insulin has proved less successful and even controversial thus far. MannKind’s development of Afrezza, an inhaled insulin delivered through a device that fits in the palm of the hand, took several tries to get FDA approval and then only succeeded with requirements that included spirometry to rule out patients with compromised lung function.
Mann spent more than $1 billion of his own money to bring Afrezza to market, and he briefly replaced the CEO last winter as the company fell woefully short of sales targets when payers refused to cover the product without prior authorization. Some patients have raved about the product’s ability to keep glycemic levels tightly in check, but Sanofi announced in early January it was ending an agreement to market the product.
In recent weeks, Chief Financial Officer Matthew Pfeffer took the helm and Mann left the board, though he was to stay on in a consulting capacity.
The Los Angeles Times, quoting Pfeffer, said Mann died in Las Vegas, where he spent most of his time.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen